ALA-105 / Arovella Therap, SparX - LARVOL DELTA

AROVELLA FULLY FUNDED TO COMPLETE PHASE 1 WITH $20M PLACEMENT (Arovella Therap Press Release) - "Arovella Therapeutics...pleased to announce that it has received firm commitments from institutional and sophisticated investors, to raise approximately $20 million (before costs) under a placement of 117.6 million new fully paid....Funds raised under the Placement will be used to complete and report data from the planned phase 1, first-in-human clinical trial for Arovella’s lead product, ALA-101. The phase 1 clinical trial is for patients with CD19- positive non-Hodgkin’s lymphoma and leukemia. Funds raised under the placement will also be used to strengthen Arovella’s iNKT cell therapy pipeline and advance Arovella’s solid tumour products, and for general working capital purposes."

Financing • Gastric Cancer • Leukemia • Non-Hodgkin’s Lymphoma • Pancreatic Cancer

AROVELLA FULLY FUNDED TO COMPLETE PHASE 1 WITH $20M PLACEMENT (Arovella Therap Press Release) - "Over the remainder of CY2025, Arovella expects to achieve several critical milestones, including: Securing IND approval through the US FDA to conduct a phase 1 clinical trial in CD19-positive non-Hodgkin’s lymphoma and leukemia; Commencing a phase 1 clinical trial; Obtaining clinical data from initial patients dosed with ALA-101; and Securing proof-of-concept data for its solid tumour programs directed toward gastric and/or pancreatic cancer."

IND • New P1 trial • Preclinical • Gastric Cancer • Leukemia • Non-Hodgkin’s Lymphoma • Pancreatic Cancer

Arovella Therapeutics' cell therapies potential highlighted in Spark Plus note (Proactiveinvestors) - "A new desk note from Spark Plus analyst Cyprus Sia has provided a comprehensive look at Arovella Therapeutics Ltd (ASX:ALA) and the work the biotech company is doing towards developing invariant natural killer T (iNKT) cell therapies, including its pioneering ‘armoured’ CAR-iNKT product...The company intends to commence a Phase 1 clinical trial for CD19+ lymphoma and leukaemia patients in late 2024....By the end of 2024, ALA will attempt to produce CLDN18.2- iNKT cells, integrate IL-12-TM into its solid tumour programs, and validate their activities in preclinical studies."

New P1 trial • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pancreatic Cancer • Solid Tumor

Arovella Therapeutics to fully focus on lead cancer programs on terminating DKK1 licence (Investing.com) - "Following a strategic review of its pipeline, Arovella Therapeutics Ltd...has terminated its licence agreement with MD Anderson Cancer Centre for the DKK1-targeting technology as it concentrates on its invariant Natural Killer T (iNKT) cell therapy platform. This decision enables the company to focus resources on its lead program, ALA-101 for CD19+ blood cancers, and the newly licensed ALA-105 for Claudin 18.2+ solid tumours, as well as its ongoing collaboration with Imugene Ltd, combining ALA-101 with Imugene’s onCARlytics platform, and the potential acquisition of a cytokine technology from the Lineberger Comprehensive Cancer Center."

Licensing / partnership • Hematological Malignancies • Oncology • Solid Tumor